Drug Profile
WT 501
Alternative Names: WT501Latest Information Update: 02 Feb 2021
Price :
$50
*
At a glance
- Originator Wellstat Therapeutics Corporation
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Mitochondrial disorders
Most Recent Events
- 02 Feb 2021 Discontinued - Phase-II for Mitochondrial disorders (PO)
- 06 Oct 2016 Phase-II clinical trials in Mitochondrial disorders (PO) (Wellstat Therapeutics pipeline, October 2016)